StreetInsider.com News Articles

Form 6-K Polyrizon Ltd. For: Oct 27

Tue, 27 Oct 2026 08:38:00 -0400

si-local-file:///var/storage/secattach/20261027/27237478.html

Polyrizon completes enrollment of 120 patients in U.S. Nasarix study

Tue, 27 Oct 2026 08:16:30 -0400

Polyrizon Ltd. (Nasdaq: PLRZ) announced the completion of patient enrollment in its U.S. multicenter clinical study evaluating NASARIX, an investigational nasal hydrogel product candidate intended to protect against airborne allergens.

The company said 120 participants were randomized across five clinical research sites in the United States, reaching the study's planned enrollment target. A total of 144 individuals were screened to achieve that number.

The randomized, controlled study compares NASARIX against a saline control and is designed to assess the product's performance in managing symptoms of allergic rhinitis in adults. NASARIX uses Polyrizon's Capture and Contain technology, which the company says forms a

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

Tue, 27 Oct 2026 08:16:00 -0400

All 120 planned participants randomized across five clinical sites in the United States

Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful completion of patient enrollment and randomization in its U.S. multicenter clinical study evaluating NASARIX, the Company's proprietary investigational nasal hydrogel product candidate designed to provide protection against airborne allergens.

The study has reached its planned enrollment target, with 120 participants randomized across five clinical research sites in the United

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker

Tue, 27 Oct 2026 08:16:00 -0400

All 120 planned participants randomized across five clinical sites in the United States

The study has reached its planned enrollment target, with 120 participants randomized across five clinical research sites in the United

Form S-8 Polyrizon Ltd.

Wed, 07 Oct 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20261007/27161457.html

Form 6-K Polyrizon Ltd. For: Oct 05

Mon, 05 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27148565.html

Polyrizon files U.S. divisional patent for nasal drug delivery platform

Mon, 05 Oct 2026 07:33:09 -0400

Polyrizon Ltd. (NASDAQ: PLRZ), a clinical-stage biotechnology company based in Raanana, Israel, has filed a divisional patent application with the United States Patent and Trademark Office covering its mucoadhesive polymer technology for nasal drug delivery.

The application, titled "Mucoadhesive Polymers for Nasal Drug Delivery," was assigned U.S. Patent Application No. 19/823,285. The filing is part of an existing U.S. patent family and is intended to pursue protection for distinct aspects of the company's technology.

The technology involves polymeric compositions designed to adhere to mucosal surfaces and form a continuous layer upon contact with mucosal tissue. The patent family describes the potential incorporation

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Mon, 05 Oct 2026 07:32:00 -0400

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.

Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has filed a new U.S. divisional patent application with the United States Patent and Trademark Office (USPTO), further expanding the Company’s intellectual property portfolio relating to its proprietary mucoadhesive technology.

The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S. Patent Application No.

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform

Mon, 05 Oct 2026 07:32:00 -0400

A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery.

The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S. Patent Application No.

Form EFFECT Polyrizon Ltd.

Fri, 02 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27138607.html

Form F-1/A Polyrizon Ltd.

Mon, 28 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260928/27114867.html

Form 6-K Polyrizon Ltd. For: Jun 30

Mon, 28 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260928/27114661.html

Polyrizon enrolls first patient in U.S. allergy blocker study

Tue, 22 Sep 2026 08:35:07 -0400

Polyrizon Ltd. (Nasdaq: PLRZ) announced the enrollment of the first patient in a U.S. clinical study evaluating its investigational nasal spray, NASARIX (PL-14), for the treatment of seasonal allergic rhinitis, according to a press release dated Sept. 22, 2026.

The enrollment marks the company's transition from a preclinical to a clinical-stage biotech. Polyrizon is based in Raanana, Israel, and specializes in intranasal hydrogel medical devices.

NASARIX is a drug-free, mucoadhesive hydrogel nasal spray designed to form a physical barrier in the nasal cavity intended to reduce contact between airborne allergens and the nasal mucosa.

The study is a prospective, multicenter, randomized, single-blind, two-arm

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Tue, 22 Sep 2026 08:33:00 -0400

First patient marks Polyrizon’s transition into a clinical-stage company.

The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis

Raanana, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical- stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the enrollment of the first patient in its U.S. clinical study to evaluate NASARIX (PL-14), the Company’s investigational Allergy Blocker, in patients with seasonal allergic rhinitis (SAR).

The enrollment

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Tue, 22 Sep 2026 08:33:00 -0400

First patient marks Polyrizon’s transition into a clinical-stage company.

The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis

The enrollment

Form F-1 Polyrizon Ltd.

Fri, 18 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260918/27080896.html

Form D Polyrizon Ltd.

Thu, 10 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260910/27048615.html

Polyrizon launches $4M registered direct offering and private placement

Thu, 03 Sep 2026 08:50:37 -0400

Polyrizon Ltd. (NASDAQ: PLRZ), a development-stage biotech company based in Raanana, Israel, announced it has entered into definitive agreements with a single institutional investor for a registered direct offering and concurrent private placement, with aggregate gross proceeds expected to reach approximately $4.0 million.

The transactions involve the sale of 333,333 units, each consisting of one ordinary share, or one pre-funded warrant to purchase one ordinary share, and one common warrant to purchase one ordinary share. The combined offering price is $12.00 per unit, or $11.99999 per pre-funded unit. In the registered direct offering, the company agreed to sell 232,500 ordinary shares

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Thu, 03 Sep 2026 08:50:00 -0400

RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $4.0 million.

The transactions

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement

Thu, 03 Sep 2026 08:50:00 -0400

The transactions

Polyrizon signs all five U.S. sites for NASARIX allergy trial

Wed, 02 Sep 2026 07:32:54 -0400

Polyrizon Ltd. (Nasdaq: PLRZ) has completed contracts with all five U.S. clinical sites selected for its first-in-human study of NASARIX™ Allergy Blocker (PL-14), according to a company statement.

The planned study is a prospective, multicenter, randomized, single-blind, two-arm clinical trial designed to evaluate the efficacy, safety, and tolerability of NASARIX™ in patients with seasonal allergic rhinitis. The trial aims to enroll up to 120 randomized patients, assigned in a 1:1 ratio to receive either NASARIX™ or an isotonic saline nasal spray control.

The primary efficacy endpoint will measure the difference between treatment groups in mean daily reflective Total Nasal Symptom Score over

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Wed, 02 Sep 2026 07:32:00 -0400

Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14).

With the execution of these final agreements, Polyrizon has completed the contracting with all five U.S. clinical sites selected for the study, marking an important operational milestone and moves the NASARIX™ program into study execution. The planned first-in-human study is a prospective, multicenter, randomized, single-blind,

Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

Wed, 02 Sep 2026 07:32:00 -0400

Form 6-K Polyrizon Ltd. For: Aug 20

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956044.html

Form 6-K Polyrizon Ltd. For: Aug 20

Thu, 20 Aug 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26956044.html